乳腺癌保乳术后放疗与化疗顺序的预后价值
回顾性分析1154例T1-2N0-3M0乳腺癌患者,保乳术后均接受序贯放化疗,其中603例先放疗、551例先化疗。全组5年无病生存率为93.0%、总生存率为97.8%;先化疗组与先放疗组的总生存率和无病生存率无显著差异,但不同分子亚型中顺序的预后价值不同。
要点
- 全组5年无病生存率93.0%,总生存率97.8%。
- 先放疗组与先化疗组5年总生存率98.6%对96.4%(P=0.191),无病生存率92.7%对93.2%(P=0.430),均无显著差异。
- 三阴性乳腺癌先放疗组5年总生存率100%高于先化疗组90.9%(P=0.019),HER-2阳性先化疗组5年无病生存率100%高于先放疗组80.1%(P=0.045)。
核心结论
- 保乳术后先化疗组与先放疗组的总生存率和无病生存率无显著差异。
- HER-2阳性乳腺癌先化疗组无病生存率高于先放疗组,三阴性乳腺癌先放疗组总生存率优于先化疗组。
- 作者认为需进一步研究不同分子分型在不同放化疗顺序中的获益。
研究设计与样本
- 回顾性分析1154例T1-2N0-3M0乳腺癌患者,保乳术后均接受序贯放疗和化疗。
- 其中603例先放疗,551例先化疗。
- 采用Log-rank检验比较Kaplan-Meier曲线上的无病生存率和总生存率。
主要发现
- 全组5年无病生存率为93.0%,总生存率为97.8%。
- 先放疗组与先化疗组5年总生存率分别为98.6%和96.4%(P=0.191),无病生存率分别为92.7%和93.2%(P=0.430)。
- Luminal A型中先放疗组与先化疗组5年总生存率分别为99.6%和97.8%(P=0.789)。
- Luminal B型中先放疗组与先化疗组5年总生存率分别为94.2%和96.0%(P=0.680)。
- 三阴性乳腺癌中先放疗组与先化疗组5年总生存率分别为100%和90.9%,差异有统计学意义(P=0.019)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the prognostic value of sequencing of adjuvant radiotherapy and chemotherapy following breast-conserving surgery for patients with breast cancer. Methods: A total of 1 154 patients withT1-2N0-3M0 breast cancer retrospectively reviewed. All patients received sequential radiotherapy and chemotherapy following breast-conserving surgery. Among them, 603 patients received radiotherapy first and 551 patients received chemotherapy first. Log-rank tests were used to determine significance of disease-free survival (DFS) and overall survival (OS) rates in the Kaplan-Meier curve. Results: The 5-year DFS and OS rates for all patients were 93.0% and 97.8%. The 5-year OS rate was 98.6% in the radiotherapy first group and 96.4% in the chemotherapy first group (P=0.191), and the corresponding DFS rate was 92.7% and 93.2% (P=0.430), respectively. Among the patients with Luminal A subtype, the 5-year OS rate was 99.6% in the radiotherapy first group and 97.8% in the chemotherapy first group (P=0.789). Among the patients with Luminal B subtype, the 5-year OS rate was 94.2% and 96.0%, respectively (P=0.680). Among the patients with triple negative breast cancer, the 5-year OS rate was 100% and 90.9%, respectively, with statistically significant differences (P=0.019). Among the patients with HER-2 positive breast cancer, The 5-year DFS rate was 80.1% and 100%, respectively (P=0.045). Conclusions: The OS and DFS rates in the chemotherapy first group are not significantly different from those of radiotherapy first group after breast-conserving surgery. Patients with HER-2 positive breast cancer in chemotherapy first group have a much higher DFS rate than that of radiotherapy first group, whereas patients with triple negative breast cancer in radiotherapy first group have a better OS rate than that of chemotherapy first group. Further research is warranted to investigate the benefit of different molecular types in different sequencing of radiotherapy and chemotherapy after breast-conserving surgery.
引用
- Zhong QZ, Wang Z, Tang Y, et al. [Prognostic value of sequencing of radiotherapy and chemotherapy following breast-conserving surgery for patients with breast cancer]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28550675. doi:10.3760/cma.j.issn.0253-3766.2017.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。